Regulating E-Pharmacies in India: Gaps in the Drugs and Cosmetics Act and the Need for a Dedicated Legal Framework

[1]Virendra Kumar, [2]Deepmala, [3]Mohak Jolly, [4]Kashish Pushkar, [5]Sanjay Singh Rawat

[1]Assistant Professor, Royal College of Law, Ghaziabad, Uttar Pradesh
[2]Assistant Professor, IME Law College, Sahibabad, Uttar Pradesh
[3]Assistant Professor, Royal College of Law, Ghaziabad, Uttar Pradesh
[4]B.A.LL.B., Jigyasa University, Dehradun, Uttarakhand
[5]Assistant Professor, Jigyasa University, Dehradun, Uttarakhand

Abstract

The emergence of e-pharmacies in India has revolutionized pharmaceutical retail by enhancing accessibility, affordability, and convenience in medicine distribution. However, the rapid growth of online pharmaceutical services has exposed critical regulatory gaps in the existing legal framework, primarily the Drugs and Cosmetics Act, 1940, which predates the digital era and lacks provisions specifically addressing e-pharmacy operations. This research paper examines the regulatory lacunae governing e-pharmacies in India, analyzing the inadequacies of current legislation, the challenges posed by the absence of a dedicated legal framework, and the implications for patient safety, data protection, and pharmaceutical accountability. Through a comprehensive analysis of existing laws, draft regulations, judicial interventions, and comparative frameworks from international jurisdictions, this paper argues that India urgently requires a robust, technology-adaptive legal regime to regulate e-pharmacies effectively. The study identifies key regulatory gaps including interstate drug sale ambiguities, prescription verification mechanisms, data localization requirements, and intermediary liability, while proposing a multipronged regulatory approach encompassing mandatory registration, stringent licensing requirements, prescription validation protocols, and enhanced monitoring mechanisms. The paper concludes that only through a dedicated legislative framework can India balance the transformative potential of e-pharmacies with the imperative of public health protection.

Keywords: E-pharmacy, Drugs and Cosmetics Act 1940, pharmaceutical regulation, digital health, telemedicine, drug safety, regulatory gaps, prescription verification, data protection, online pharmacy legislation

I. Introduction

The Indian pharmaceutical landscape is undergoing a paradigmatic transformation with the advent of e-pharmacies, representing a convergence of healthcare delivery and digital technology. E-pharmacies, defined as online platforms facilitating the sale, distribution, and delivery of pharmaceutical products through digital interfaces, have emerged as significant players in India's healthcare ecosystem[1]. The sector, valued at approximately INR 4,100 crores in 2021, has witnessed exponential growth, particularly accelerated by the COVID-19 pandemic which necessitated contactless healthcare solutions[2].

The proliferation of e-pharmacy platforms such as PharmEasy, 1mg, Netmeds, and Medlife has fundamentally altered consumer behavior regarding pharmaceutical access. These platforms promise enhanced convenience through doorstep delivery, competitive pricing through aggregation economies, improved medication adherence through digital reminders, and expanded geographical reach to underserved populations[3]. The sector has attracted substantial investment exceeding $700 million and created over 30,000 employment opportunities, signaling robust market confidence[4].

However, this digital disruption has simultaneously exposed critical regulatory deficiencies in India's pharmaceutical governance architecture. The Drugs and Cosmetics Act, 1940, which constitutes the primary legislative framework for pharmaceutical regulation in India, was enacted in a pre-digital era and contains no explicit provisions addressing online pharmaceutical transactions[5]. This legislative vacuum has generated significant legal uncertainty, jurisdictional ambiguities, and concerns regarding patient safety, prescription authenticity, data privacy, and pharmaceutical quality assurance.

The regulatory challenges are compounded by the unique characteristics of e-pharmacy operations, which transcend traditional geographical boundaries, involve complex technological intermediation, generate sensitive health data, and operate through diverse business models including inventory-based and marketplace aggregation approaches[6]. The absence of clear regulatory guidelines has led to proliferation of potentially non-compliant operators, concerns about counterfeit medication distribution, prescription fraud, and inadequate consumer protection mechanisms.

This research paper undertakes a comprehensive examination of the regulatory gaps governing e-pharmacies in India, analyzing the structural inadequacies of existing legislation and articulating the necessity for a dedicated, technology-adaptive legal framework. The study proceeds through systematic analysis of current legal provisions, identification of critical regulatory gaps, examination of judicial interventions, comparative analysis of international regulatory models, and formulation of policy recommendations for establishing a robust e-pharmacy regulatory regime in India.

II. Current Legal Framework Governing E-Pharmacies in India

A. The Drugs and Cosmetics Act, 1940 and Rules, 1945

The Drugs and Cosmetics Act, 1940 (D&C Act) constitutes the foundational legislation regulating the manufacture, distribution, and sale of drugs and cosmetics in India[7]. The Act establishes a dual regulatory architecture involving both central and state authorities, with the Drugs Controller General of India (DCGI) serving as the apex regulatory authority and State Drug Controllers implementing regulations within their respective jurisdictions[8].

The D&C Act mandates that any person engaged in the sale, distribution, or stocking of pharmaceutical products must obtain appropriate licenses from designated licensing authorities[9]. The Act prescribes detailed requirements regarding premises standards, qualified pharmacist employment, record maintenance, and quality control protocols. However, these provisions were designed exclusively for traditional brick-and-mortar pharmaceutical establishments and contain no recognition of digital pharmaceutical distribution channels.

The Drugs and Cosmetics Rules, 1945, which operationalize the D&C Act, similarly lack provisions addressing e-pharmacy operations. Rules 59, 61, and 62 specifically mandate that pharmacies may sell medicines only within the jurisdiction of the licensing authority, creating significant ambiguity regarding interstate pharmaceutical transactions conducted through digital platforms[10]. This jurisdictional limitation poses fundamental challenges for e-pharmacies, which by their inherent nature operate across state boundaries through centralized digital platforms.

B. The Pharmacy Act, 1948

The Pharmacy Act, 1948 regulates pharmacy practice in India, establishing standards for pharmaceutical education, registration of pharmacists, and professional conduct[11]. Section 42 of the Act stipulates that only registered pharmacists may dispense prescription medications, thereby requiring personal professional intervention in pharmaceutical transactions. The Pharmacy Practice Regulations, 2015 further mandate that pharmacists must provide patient counseling regarding drug usage, adverse effects, contraindications, and appropriate administration protocols[12].

These provisions present significant operational challenges for e-pharmacy platforms, which rely on technology-mediated pharmaceutical distribution rather than face-to-face pharmacist-patient interactions. The Act does not address how pharmacist counseling requirements can be fulfilled in digital contexts, creating legal uncertainty regarding compliance with professional practice standards in online pharmaceutical transactions.

C. Information Technology Act, 2000

In the absence of pharmaceutical-specific digital regulations, e-pharmacies have been conceptualized under the Information Technology Act, 2000 (IT Act) as technology platforms facilitating commercial transactions[13]. Section 2(1)(w) of the IT Act defines "intermediaries" as entities providing digital infrastructure for information transmission, which potentially encompasses e-pharmacy platforms operating on marketplace models[14].

Section 79 of the IT Act provides intermediaries with conditional immunity from liability for third-party content, provided they demonstrate due diligence and expeditiously remove unlawful content upon knowledge acquisition[15]. This framework has been invoked by marketplace-based e-pharmacies arguing that they merely facilitate connections between licensed pharmacies and consumers without directly engaging in pharmaceutical sales. However, this interpretation remains contentious, particularly regarding inventory-based e-pharmacy models that maintain pharmaceutical stocks and directly fulfill consumer orders.

The IT Act also establishes data protection obligations, including reasonable security practices for sensitive personal information, which encompasses health data generated through e-pharmacy transactions[16]. However, the Act lacks healthcare-specific data protection provisions, failing to address unique privacy concerns associated with pharmaceutical purchase records, prescription data, and health condition information.

D. Draft E-Pharmacy Rules, 2018

Recognizing the regulatory vacuum surrounding e-pharmacies, the Ministry of Health and Family Welfare published Draft Rules for sale of drugs by e-pharmacy vide G.S.R. 817(E) dated August 28, 2018, proposing amendments to the Drugs and Cosmetics Rules, 1945[17]. These Draft Rules represented the first legislative attempt to specifically address e-pharmacy operations in India.

The Draft Rules propose insertion of Part VI-B into the Drugs and Cosmetics Rules, 1945, establishing a comprehensive regulatory framework for e-pharmacies. Key provisions include mandatory registration of e-pharmacy platforms with the Central Licensing Authority, requirements for 24/7 customer support and grievance redressal mechanisms staffed by registered pharmacists, prohibition on pharmaceutical advertising through digital platforms, and strict data localization mandates requiring all e-pharmacy data to be stored exclusively within India[18].

The Draft Rules also prescribe detailed procedures for pharmaceutical distribution, including verification of prescription authenticity, validation of prescriber credentials, maintenance of comprehensive transaction records, and prohibition on sale of Schedule X drugs, narcotics, and psychotropic substances through e-pharmacy channels[19]. The Rules establish periodic inspection mechanisms, complaint resolution procedures, and penalties for non-compliance including registration suspension and cancellation.

However, despite stakeholder consultations and approval by the Drug Technical Advisory Body, these Draft Rules have remained unnotified for over seven years, creating continued legal uncertainty in the sector[20]. The prolonged delay has been attributed to ongoing litigation, stakeholder opposition from traditional pharmacy associations, and policy deliberations regarding appropriate regulatory approaches.

E. The Drugs, Medical Devices, and Cosmetics Bill, 2023

The Ministry of Health and Family Welfare released the Drugs, Medical Devices, and Cosmetics Bill, 2023 (Draft Bill 2023), proposing comprehensive replacement of the Drugs and Cosmetics Act, 1940[21]. The Draft Bill 2023 represents a significant departure from the 2018 Draft Rules regarding e-pharmacy regulation.

The Draft Bill 2023 contains a crucial provision stating that "the Central Government may regulate, restrict or prohibit the sale or distribution of any drug by online mode, by notification"[22]. This language marks a fundamental shift from the permissive framework envisaged in the 2018 Draft Rules, instead conferring broad discretionary powers upon the Central Government to comprehensively regulate, restrict, or even completely prohibit e-pharmacy operations through executive notifications.

This regulatory approach has generated substantial controversy within the e-pharmacy sector, with stakeholders expressing concerns about regulatory uncertainty, potential arbitrary restrictions, and the absence of explicit permission frameworks for legitimate e-pharmacy operations[23]. The Draft Bill's approach contrasts sharply with global regulatory trends favoring structured permission-based frameworks that enable innovation while ensuring safety standards.

III. Critical Regulatory Gaps in the Current Framework

A. Absence of Clear Definitional Framework

The existing legal framework lacks a precise statutory definition of "e-pharmacy," creating foundational ambiguity regarding which entities and operational models fall within regulatory scope[24]. The 2018 Draft Rules define e-pharmacy as "a platform for facilitating the online sale and distribution of drugs," but this definition remains unofficial pending rule notification. The absence of definitive statutory language enables diverse interpretations regarding whether the term encompasses only marketplace aggregators, inventory-based retailers, telemedicine-integrated platforms, or pharmaceutical comparison portals.

This definitional ambiguity extends to related concepts including "online prescription," "digital verification," "telepharmacy," and "remote pharmaceutical consultation," none of which receive statutory recognition in current legislation. The lack of clear definitional boundaries impedes effective regulatory enforcement, creates compliance uncertainty for businesses, and enables potential regulatory arbitrage through definitional manipulation.

B. Interstate Sale and Jurisdictional Ambiguities

The territorial limitation provisions in the Drugs and Cosmetics Rules, 1945, which restrict pharmaceutical sales to the licensing authority's jurisdiction, create fundamental incompatibility with e-pharmacy operations that inherently function on pan-India or multi-state basis[25]. Rules 59, 61, and 62 mandate that retail and wholesale licenses authorize sales only within specific state boundaries, yet e-pharmacies operate through centralized digital platforms serving consumers across multiple states simultaneously.

This jurisdictional ambiguity generates multiple regulatory complications including uncertainty regarding which State Drug Controller possesses enforcement jurisdiction over interstate pharmaceutical transactions, potential requirements for obtaining separate licenses in each state where deliveries occur, ambiguities regarding applicable state-specific pharmaceutical regulations, and challenges in complaint resolution when consumers, sellers, and intermediaries are located in different states[26].

The Mumbai Food and Drug Administration has already registered cases involving interstate pharmaceutical sales through e-platforms, highlighting the practical enforcement challenges arising from jurisdictional ambiguities[27]. Without clear legislative resolution of interstate commerce issues, e-pharmacies face continuing legal uncertainty and potential compliance violations despite good-faith operational attempts.

C. Prescription Verification and Authentication Deficiencies

Ensuring prescription authenticity constitutes a critical patient safety imperative, yet current regulations provide inadequate guidance regarding verification mechanisms appropriate for digital pharmaceutical transactions[28]. The Drugs and Cosmetics Act mandates that Schedule H and Schedule X drugs may be sold only against valid prescriptions from registered medical practitioners, but these provisions presuppose physical prescription presentation to pharmacists who can assess authenticity through established professional protocols.

E-pharmacy platforms receive prescriptions through digital uploads, scans, photographs, or electronic prescription systems, creating novel authentication challenges including inability to verify original prescription documents, difficulty detecting forged or manipulated prescriptions, challenges confirming prescriber identity and registration status, and absence of standardized digital prescription formats[29]. The 2018 Draft Rules require e-pharmacies to verify patient and prescriber authenticity but provide no specific technical standards or verification protocols.

Furthermore, current regulations fail to address the validity period of prescriptions in digital contexts, the legitimacy of prescriptions generated through telemedicine consultations, requirements for electronic signatures or digital authentication, and procedures when prescription verification systems fail or generate uncertain results[30]. These gaps create significant patient safety risks, including potential for prescription fraud, unauthorized access to controlled substances, inappropriate self-medication, and inadequate pharmaceutical counseling.

D. Data Protection and Privacy Concerns

E-pharmacy operations generate extensive sensitive personal data including medical conditions, prescription histories, medication adherence patterns, and health-related consumer behavior[31]. This data possesses significant commercial value for pharmaceutical marketing, insurance underwriting, and health analytics, while simultaneously presenting substantial privacy risks if inadequately protected or improperly disclosed.

The existing legal framework provides minimal healthcare-specific data protection provisions. While the IT Act establishes general obligations for reasonable security practices regarding sensitive personal data, it lacks provisions addressing unique healthcare data sensitivities, patient consent requirements for data collection and processing, limitations on secondary data usage and commercial exploitation, and data breach notification obligations specific to health information[32].

The 2018 Draft Rules include data localization mandates requiring e-pharmacy data storage exclusively within India, but they do not comprehensively address data protection issues including patient consent mechanisms, data minimization principles, purpose limitation requirements, data retention periods, patient data access and correction rights, and third-party data sharing restrictions[33]. The enactment of the Digital Personal Data Protection Act, 2023, establishes general data protection principles, but healthcare-specific regulations remain necessary to address unique pharmaceutical data sensitivities.

E. Quality Assurance and Counterfeit Prevention

The risk of counterfeit, substandard, or spurious pharmaceutical products entering supply chains through digital platforms represents a critical regulatory concern[34]. Traditional pharmaceutical distribution involves physical inspections, established supplier relationships, and traceable supply chains, whereas e-pharmacy platforms may aggregate multiple pharmaceutical sources, creating potential vulnerabilities in quality assurance systems.

Current regulations lack specific provisions addressing pharmaceutical authentication in digital contexts, including requirements for drug barcoding or serialization at manufacturing level to enable digital verification, mandatory integration with Track and Trace systems for pharmaceutical supply chain monitoring, authentication protocols for verifying pharmaceutical legitimacy before digital platform listing, and cold chain maintenance verification for temperature-sensitive medications distributed through e-pharmacy channels[35].

The absence of these quality assurance mechanisms creates risks of counterfeit pharmaceutical infiltration, distribution of expired or improperly stored medications, supply chain opacity preventing contamination source identification, and inadequate accountability when quality failures occur. While the 2018 Draft Rules establish complaint redressal mechanisms for quality concerns, they lack preventive quality assurance standards appropriate for digital pharmaceutical distribution.

F. Ambiguity Regarding Business Models and Intermediary Liability

E-pharmacies operate through diverse business models including inventory-based models where platforms directly stock pharmaceuticals and fulfill orders, and marketplace models where platforms facilitate connections between independent licensed pharmacies and consumers[36]. These distinct operational structures carry different liability implications, yet current regulations fail to differentiate between models or establish appropriate liability frameworks.

Marketplace-based e-pharmacies invoke Section 79 of the IT Act to claim intermediary immunity from liability for pharmaceutical sales conducted by independent third-party pharmacies listed on their platforms[37]. However, this interpretation remains contested, particularly when platforms exert significant control over pricing, product listings, delivery logistics, and customer relationships. The question of when platforms transition from mere intermediaries to active pharmaceutical sellers lacks clear legal resolution.

Furthermore, regulations fail to address platform obligations including due diligence requirements for verifying pharmacy licenses before platform listing, monitoring responsibilities for detecting prescription fraud or prohibited sales, obligations when platforms become aware of non-compliant pharmacy partners, and liability allocation when pharmaceutical defects or adverse events occur through platform-facilitated transactions[38]. These ambiguities impede effective regulatory enforcement and create accountability gaps potentially compromising patient safety.

G. Prohibition on Over-the-Counter Drug Sales

Current regulations lack clear distinction between prescription-only medications and Over-the-Counter (OTC) drugs that may be safely sold without prescriptions[39]. While the Drugs and Cosmetics Act categorizes certain medications under Schedules requiring prescriptions, India lacks a comprehensive official OTC drug classification comparable to systems in the United States, United Kingdom, and European Union jurisdictions.

This absence creates operational challenges for e-pharmacies uncertain which products may be sold without prescription requirements, potentially restricting consumer access to safe self-care medications, or alternatively risking regulatory violations through inadvertent non-prescription sales of scheduled drugs. The 2018 Draft Rules prohibit sale of Schedule X drugs, narcotics, and psychotropic substances through e-pharmacies but do not establish positive guidelines regarding permissible OTC pharmaceutical categories[40].

H. Inadequate Consumer Protection Mechanisms

E-pharmacy consumers face unique vulnerabilities including inability to physically inspect pharmaceuticals before purchase, dependence on platform-provided information regarding drug composition and effects, limited recourse mechanisms when adverse events occur, and information asymmetries regarding pharmacy credentials and pharmaceutical authenticity[41]. However, existing consumer protection frameworks inadequately address these digital-specific vulnerabilities.

Current regulations lack provisions establishing minimum information disclosure requirements for e-pharmacy platforms, standardized formats for presenting pharmaceutical information to enable informed consumer decisions, mandatory adverse event reporting systems for pharmaceuticals distributed through digital channels, and accessible dispute resolution mechanisms for consumer complaints regarding pharmaceutical quality or delivery issues[42]. The 2018 Draft Rules require grievance redressal mechanisms but provide limited specificity regarding procedural standards, resolution timeframes, or remedial obligations.

IV. Judicial Interventions and Litigation

The regulatory vacuum surrounding e-pharmacies has generated extensive litigation, with various High Courts intervening to address legal uncertainties and potential public health risks. These judicial interventions have produced divergent outcomes, reflecting underlying tensions between innovation facilitation and health protection imperatives.

A. Tamil Nadu Chemists and Druggists Association v. Union of India

In December 2018, the Madras High Court issued an interim order restraining e-pharmacies from conducting online pharmaceutical sales until the Draft E-Pharmacy Rules, 2018 were officially notified[43]. The petition was filed by the Tamil Nadu Chemists and Druggists Association, representing traditional retail pharmacies, arguing that e-pharmacy operations violated the Drugs and Cosmetics Act and Pharmacy Act by operating without appropriate registrations, posed risks of counterfeit pharmaceutical distribution, and undermined retail pharmacy businesses.

The Single Judge observed that the Drugs and Cosmetics Act preceded the computer and internet era, creating ambiguity regarding applicability to online pharmaceutical sales. The Court expressed concerns regarding potential distribution of harmful, fake, or contaminated medicines through inadequately regulated digital platforms, concluding that online pharmaceutical sales should be suspended pending clear regulatory framework establishment[44].

However, a Division Bench of the Madras High Court subsequently stayed this order, observing that agencies established under the Drugs and Cosmetics Act possessed authority to take appropriate enforcement action against regulatory violations without necessitating judicial intervention. The Division Bench further noted that abrupt prohibition on online pharmaceutical sales would cause significant hardship to patients who had come to rely on e-pharmacy services for medication access[45]. The case was disposed of in June 2024, with the Court directing the Central Government to expedite policy formulation regarding online pharmaceutical sales.

B. Dr. Zaheer Ahmed v. Union of India

In December 2018, the Delhi High Court, in *Dr. Zaheer Ahmed v. Union of India*, issued an order interpreted by some reports as imposing a nationwide ban on online pharmaceutical sales[46]. The petitioner, a dermatologist, filed the case after discovering that his patient had purchased Schedule X controlled drugs online without prescriptions, raising serious concerns regarding prescription circumvention and controlled substance access through digital platforms.

The Court observed that e-pharmacy platforms were openly flouting provisions of the Drugs and Cosmetics Act and Pharmacy Act by operating without proper registrations and exposing the public to substandard pharmaceutical products. However, the exact scope and continued effect of this order remain subject to interpretation and subsequent proceedings.

C. Delhi High Court Directions (2023-2024)

In November 2023, the Delhi High Court directed the Central Government to frame a comprehensive policy for online pharmaceutical sales within eight weeks and inform the Court about stakeholder consultation outcomes regarding the Draft Rules[47]. The Court observed that the Draft Rules had been pending for over five years since their 2018 publication, creating unacceptable regulatory uncertainty requiring urgent resolution.

When the Government failed to frame the policy within the stipulated timeframe, the Court in March 2024 granted a final four-month extension, warning that failure to act would result in the Court adjudicating the matter on merits[48]. These judicial directives underscore growing judicial impatience with prolonged governmental inaction on e-pharmacy regulation despite recognized public health implications.

V. Comparative Analysis: International E-Pharmacy Regulatory Models

Examining international regulatory approaches provides valuable insights for developing an appropriate Indian e-pharmacy framework. Different jurisdictions have adopted varied regulatory philosophies balancing innovation facilitation with patient safety protection.

A. United States: The Ryan Haight Act

The United States regulates e-pharmacies primarily through the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, which amended the Controlled Substances Act[49]. The legislation mandates that e-pharmacies may sell controlled substances only based on valid prescriptions issued after in-person medical examinations, except in specifically enumerated telemedicine circumstances meeting stringent requirements.

The Act requires online pharmacies to display registration information from the Drug Enforcement Administration and State Boards of Pharmacy prominently on their websites. E-pharmacies must implement secure systems for collecting, utilizing, and storing customer information, along with secure payment processing mechanisms[50]. The stringent prescription verification requirements, including mandatory in-person consultations for initial controlled substance prescriptions, establish high patient safety standards while potentially limiting telemedicine integration benefits.

B. United Kingdom: General Pharmaceutical Council Regulations

The United Kingdom regulates e-pharmacies through the General Pharmaceutical Council (GPhC), which requires all online pharmacies to register and display a mandatory internet pharmacy logo verifying their legitimate status[51]. Registered e-pharmacies must comply with comprehensive standards including verification procedures before dispensing medications, though the GPhC grants flexibility in verification methodologies rather than prescribing specific technical protocols.

UK regulations emphasize professional pharmacist involvement in online pharmaceutical transactions, requiring that registered pharmacists make final dispensing decisions and remain available for patient consultations. E-pharmacies must operate from registered pharmacy premises subject to physical inspections, ensuring integration with traditional pharmaceutical quality standards[52]. This model balances operational flexibility with professional accountability through pharmacist oversight requirements.

C. Kenya: E-Pharmacy Regulatory Framework

Kenya has established a formal e-pharmacy regulatory framework through the Pharmacy and Poisons Board, providing a relevant comparison as a developing economy with healthcare access challenges comparable to India[53]. The Kenyan framework establishes explicit registration requirements, operational standards, and enforcement mechanisms specifically designed for digital pharmaceutical distribution.

Recent comparative studies indicate that Kenyan e-pharmacies demonstrate better regulatory compliance in certain dimensions compared to Indian platforms, including higher rates of prescription upload facilities, greater transparency regarding pharmacy registration information, and more consistent implementation of grievance redressal mechanisms[54]. The existence of a clear regulatory framework appears correlated with improved compliance rates, supporting the argument for dedicated e-pharmacy legislation in India.

VI. Policy Recommendations and Suggested Regulatory Framework

Based on the identified regulatory gaps, international comparative analysis, and stakeholder considerations, this section proposes a comprehensive regulatory framework for e-pharmacies in India.

A. Statutory Recognition and Clear Definitions

India should incorporate explicit statutory recognition of e-pharmacies within the pharmaceutical regulatory framework, preferably through notification of the pending Draft E-Pharmacy Rules or enactment of dedicated e-pharmacy provisions within the proposed Drugs, Medical Devices, and Cosmetics Bill[55]. The legislation should provide clear definitions distinguishing inventory-based e-pharmacies that stock and directly sell pharmaceuticals from marketplace e-pharmacies that facilitate connections between independent pharmacies and consumers.

The framework should also define related concepts including "electronic prescription," "digital prescription verification," "online pharmaceutical consultation," and "telepharmacy services," establishing clear parameters for regulatory applicability. Definitional clarity would reduce regulatory arbitrage opportunities, facilitate consistent enforcement, and provide operational certainty for legitimate business models.

B. Mandatory Registration and Licensing Framework

E-pharmacies should be required to obtain mandatory registration from the Central Licensing Authority, as proposed in the 2018 Draft Rules, ensuring centralized regulatory oversight appropriate for inherently interstate digital operations[56]. The registration framework should establish clear eligibility criteria including possession of valid pharmaceutical licenses for underlying physical premises, employment of registered pharmacists in supervisory capacities, demonstration of secure technology infrastructure for data protection, and compliance with quality assurance and supply chain integrity standards.

The licensing framework should differentiate between inventory-based and marketplace models, establishing appropriate requirements for each. Marketplace platforms should face enhanced due diligence obligations regarding verification of partner pharmacy credentials, ongoing monitoring of partner compliance, and expeditious removal of non-compliant pharmacies. Licensing conditions should include mandatory information disclosure on platforms regarding registration numbers, supervising pharmacists, grievance redressal mechanisms, and pharmaceutical sourcing information.

C. Robust Prescription Verification Mechanisms

Addressing prescription authenticity concerns requires implementation of technology-enabled verification systems. India should mandate integration of e-pharmacy platforms with the National Digital Health Mission (now Ayushman Bharat Digital Mission) and its Health Professional Registry and Health Facility Registry components[57]. This integration would enable real-time verification of prescriber credentials, ensuring that prescriptions originate from legitimately registered medical practitioners.

E-pharmacies should be required to implement Artificial Intelligence-driven prescription validation systems capable of detecting forged documents, identifying inconsistencies in prescription details, and flagging potential fraudulent patterns[58]. Regulatory standards should specify minimum verification parameters including prescriber registration validation, prescription date verification, patient identification authentication, and detection of duplicate or recycled prescriptions.

The framework should establish clear standards for electronic prescriptions generated through telemedicine consultations, including requirements for digital signatures conforming to the Information Technology Act, mandatory prescriber authentication, and electronic prescription format standards. Prescription validity periods should be explicitly specified, differentiating between acute and chronic medication prescriptions.

D. Interstate Commerce Resolution

The regulatory framework must explicitly address interstate pharmaceutical commerce through e-platforms, resolving the jurisdictional ambiguities created by current territorial licensing provisions. Legislation should clearly establish that e-pharmacies registered with the Central Licensing Authority are authorized to conduct pharmaceutical sales across state boundaries without requiring separate state-specific licenses, subject to compliance with central regulatory standards[59].

To ensure quality consistency, the framework should establish uniform national standards for pharmaceutical storage, handling, transportation, and delivery that apply to all interstate e-pharmacy operations. State Drug Controllers should retain enforcement authority regarding e-pharmacy operations within their jurisdictions but should implement harmonized standards to prevent regulatory fragmentation. The framework should designate clear jurisdictional rules for complaint resolution and enforcement actions, potentially establishing that jurisdiction lies where the consumer is located or where pharmaceutical defects are discovered.

E. Comprehensive Data Protection Framework

Given the sensitivity of pharmaceutical and health data generated through e-pharmacy operations, sector-specific data protection regulations are necessary beyond general data protection laws. E-pharmacies should be required to obtain explicit, informed consent from patients for collection and processing of health data, with clear disclosure of data usage purposes, retention periods, and potential third-party sharing[60].

The framework should implement strict purpose limitation principles, prohibiting use of pharmaceutical purchase data for purposes incompatible with healthcare delivery, such as targeted advertising of unrelated products, insurance underwriting, or employment decisions. Data minimization principles should require collection of only data necessary for pharmaceutical dispensing and delivery. Patient rights should include data access, correction, and erasure rights, subject to reasonable record retention requirements for pharmaceutical transactions.

Security standards should mandate encryption of health data during transmission and storage, regular security audits, and mandatory data breach notifications to affected patients and regulatory authorities within specified timeframes. Third-party data sharing should require patient consent except where necessary for pharmaceutical delivery or legally mandated public health purposes. Data localization requirements, as proposed in the 2018 Draft Rules, should be maintained to ensure regulatory access and prevent foreign jurisdiction complications[61].

F. Quality Assurance and Supply Chain Integrity

To prevent counterfeit pharmaceutical infiltration through e-pharmacy channels, India should mandate implementation of pharmaceutical serialization and track-and-trace systems. E-pharmacies should be required to verify pharmaceutical barcodes or unique device identifiers before listing products on platforms, enabling authentication of pharmaceutical legitimacy[62].

The framework should mandate integration of e-pharmacy systems with the Drug Authentication and Verification Application or similar centralized pharmaceutical tracking databases. Requirements for maintaining cold chain integrity for temperature-sensitive biologics and vaccines should be explicitly established, including temperature monitoring during storage and transportation, automated temperature logging systems, and alerts for temperature excursions.

Periodic inspection protocols should be established, as envisaged in the 2018 Draft Rules, with inspections conducted at least biennially covering technology infrastructure, data security systems, pharmaceutical storage facilities, and quality management procedures[63]. Surprise inspections should be authorized when quality concerns arise.

G. Restricted Pharmaceutical Categories

The regulatory framework should clearly enumerate pharmaceutical categories prohibited from e-pharmacy sale, maintaining the 2018 Draft Rules' prohibitions on Schedule X narcotics and psychotropic substances[64]. However, the framework should also establish clear guidance regarding Over-the-Counter medications permissible for sale without prescription requirements, potentially adopting a tiered classification system distinguishing prescription-only medications, pharmacist-supervised medications, and unrestricted OTC products.

Certain pharmaceutical categories requiring specialized handling, such as vaccines requiring ultra-cold chain maintenance, or injectable medications requiring administration training, should either be prohibited from e-pharmacy distribution or subject to enhanced safety protocols including verification of cold chain maintenance, confirmation of administration capability, and provision of proper usage instructions.

H. Enhanced Consumer Protection Mechanisms

E-pharmacies should face mandatory information disclosure requirements including display of registration certificates, license numbers, and supervising pharmacist details prominently on platforms. Pharmaceutical listings should include comprehensive information regarding active ingredients, therapeutic indications, contraindications, potential adverse effects, drug interactions, and proper usage instructions in standardized formats enabling informed consumer decision-making[65].

The framework should establish accessible grievance redressal mechanisms with specified response timeframes, escalation procedures, and remedial obligations. E-pharmacies should be required to implement adverse event reporting systems enabling consumers to report medication side effects or quality concerns, with mandatory forwarding of reports to pharmacovigilance authorities. Return and refund policies should be clearly disclosed, with reasonable provisions for returns when quality defects are identified or incorrect medications dispensed.

I. Professional Pharmacist Oversight

To maintain pharmaceutical care standards, regulations should mandate that registered pharmacists play active oversight roles in e-pharmacy operations. E-pharmacies should employ pharmacists responsible for verifying prescriptions, reviewing potential drug interactions, providing patient counseling through telephonic or video consultation, and making final dispensing decisions[66].

Pharmacist availability should be ensured through 24/7 customer support mechanisms staffed by registered pharmacists, as proposed in the 2018 Draft Rules. Telepharmacy regulations should establish standards for remote pharmaceutical consultation, including technology requirements, documentation obligations, and patient consent procedures. Continuing professional development requirements should be established for pharmacists engaged in e-pharmacy operations, ensuring familiarity with digital health technologies and evolving regulatory standards.

J. Monitoring, Enforcement, and Penalties

The regulatory framework should establish robust monitoring mechanisms including regular reporting requirements obligating e-pharmacies to submit transaction data, prescription volumes, and adverse event reports to regulatory authorities. Technology-enabled monitoring through APIs connecting e-pharmacy platforms with regulatory databases could facilitate real-time oversight of prescription patterns, controlled substance distribution, and potential fraudulent activities[67].

Enforcement mechanisms should include graduated penalties proportionate to violation severity. Minor violations such as information disclosure deficiencies could attract warnings and compliance directives, while serious violations such as prescription fraud facilitation, counterfeit pharmaceutical distribution, or controlled substance sales without prescriptions should result in registration suspension or cancellation, along with criminal penalties. Civil monetary penalties should be substantial enough to deter violations while considering proportionality for smaller operators.

The framework should establish clear appeal mechanisms enabling e-pharmacies to challenge regulatory decisions, ensuring procedural fairness while maintaining regulatory authority. Collaborative enforcement involving Central and State Drug Controllers, along with coordination with cybercrime authorities for technology-facilitated violations, would ensure comprehensive enforcement coverage.

VII. Challenges in Implementation

While the proposed regulatory framework addresses identified gaps, implementation would face significant challenges requiring careful navigation.

A. Stakeholder Resistance

Traditional retail pharmacies have consistently opposed e-pharmacy operations, arguing that online platforms undermine their businesses through unsustainable discount practices, erode patient-pharmacist relationships essential for pharmaceutical care, and create unfair competition through regulatory arbitrage[68]. This opposition has manifested in litigation, political lobbying, and organized protests, potentially impeding regulatory framework acceptance.

Balancing the legitimate concerns of traditional pharmacies with enabling innovation and expanding pharmaceutical access requires nuanced policy approaches. Regulatory frameworks should ensure competitive neutrality, applying equivalent quality and professional standards to both online and offline pharmaceutical distribution while recognizing operational differences justifying adapted requirements. Transition support for traditional pharmacies seeking to establish online presence or integrate with e-pharmacy platforms could facilitate sector evolution while protecting existing businesses.

B. Technology Infrastructure Limitations

Implementing sophisticated prescription verification, pharmaceutical serialization, and track-and-trace systems requires substantial technology infrastructure investments by both e-pharmacies and regulatory authorities[69]. Many smaller e-pharmacy operators may lack resources for comprehensive technology compliance, potentially creating market consolidation favoring larger platforms with greater capital access.

Regulatory authorities face challenges in developing technology capabilities for effective monitoring, data analysis, and enforcement in digital contexts. Establishing centralized prescription verification systems, pharmaceutical tracking databases, and real-time monitoring mechanisms requires significant governmental technology investment and expertise development. Phased implementation approaches with graduated compliance timelines based on operator size could facilitate smoother technology adoption.

C. Prescription Verification Practical Challenges

Despite technology enablement, prescription verification faces inherent limitations. Distinguishing legitimate prescriptions from sophisticated forgeries through digital image analysis remains technically challenging. Patients may present valid prescriptions from unregistered practitioners or foreign medical professionals, creating verification complications. Telemedicine prescriptions generated through brief online consultations may technically comply with requirements while potentially representing inappropriate prescribing practices[70].

Regulatory frameworks must balance prescription verification stringency with avoiding excessive barriers to legitimate pharmaceutical access, particularly for chronic disease patients requiring regular medication refills. Allowing prescription reuse for chronic medications within specified parameters, while requiring fresh prescriptions for acute conditions or controlled substances, could provide reasonable balance. However, defining appropriate parameters requires careful consideration of medication types, abuse potential, and patient safety implications.

D. Data Protection Compliance Costs

Implementing comprehensive data protection measures including encryption, access controls, breach detection systems, and regular security audits imposes significant compliance costs on e-pharmacy operators[71]. Smaller platforms may struggle with data protection compliance, potentially limiting market participation and reducing competition. However, given the sensitivity of health data, reduced data protection standards for smaller operators would create unacceptable privacy risks.

Regulatory authorities could potentially develop shared technology infrastructure enabling smaller operators to access compliance tools at reduced costs. Industry associations could facilitate collective data protection solutions, spreading costs across multiple operators while maintaining individual operator accountability. Clear regulatory guidance regarding minimum acceptable data protection standards, potentially with safe harbor provisions for operators implementing specified security measures, would reduce compliance uncertainty.

E. Enforcement Capacity Constraints

Effective e-pharmacy regulation requires substantial enforcement capacity involving technology expertise, pharmaceutical knowledge, and investigative capabilities. State Drug Controllers, already facing resource constraints in regulating traditional pharmaceutical sectors, may lack capacity for effective e-pharmacy oversight[72]. The inherently interstate and technology-mediated nature of e-pharmacy operations complicates enforcement, requiring coordination across multiple jurisdictions and integration with cybercrime investigation capabilities.

Capacity building initiatives including specialized training for drug inspectors in digital pharmaceutical distribution, establishment of dedicated e-pharmacy oversight units within regulatory authorities, and development of technology-enabled monitoring systems could enhance enforcement effectiveness. Public-private partnerships leveraging industry technology capabilities for regulatory compliance monitoring, subject to appropriate safeguards, could augment limited governmental resources.

VIII. Conclusion

The emergence of e-pharmacies represents a transformative development in India's pharmaceutical landscape, offering significant potential benefits including enhanced medication accessibility for geographically dispersed populations, improved affordability through reduced distribution costs and price transparency, convenience for elderly and mobility-impaired patients, and medication adherence support through digital reminder systems. The sector's growth trajectory, substantial investment attraction, and employment generation demonstrate its economic significance and market acceptance.

However, the absence of a clear, comprehensive regulatory framework creates unacceptable legal uncertainty, potential patient safety risks, and impediments to legitimate business operations. The Drugs and Cosmetics Act, 1940, despite its foundational importance in pharmaceutical regulation, reflects a pre-digital era and lacks provisions addressing unique challenges posed by technology-mediated pharmaceutical distribution. The prolonged delay in notifying the Draft E-Pharmacy Rules, 2018, combined with the potentially restrictive approach of the Draft Drugs, Medical Devices, and Cosmetics Bill, 2023, perpetuates regulatory ambiguity requiring urgent resolution.

This research has identified critical regulatory gaps including definitional ambiguities regarding e-pharmacy scope, jurisdictional uncertainties affecting interstate pharmaceutical commerce, inadequate prescription verification mechanisms enabling potential fraud, insufficient data protection provisions for sensitive health information, quality assurance deficiencies creating counterfeit pharmaceutical risks, liability ambiguities regarding diverse business models, and inadequate consumer protection mechanisms for digital pharmaceutical transactions. These gaps create risks to patient safety, pharmaceutical quality, data privacy, and market integrity.

International regulatory experiences demonstrate that clear, balanced frameworks can enable e-pharmacy innovation while maintaining safety standards. The United States' Ryan Haight Act establishes stringent prescription verification requirements ensuring controlled substance distribution accountability. The United Kingdom's model emphasizes professional pharmacist oversight in online pharmaceutical transactions. Kenya's experience demonstrates that formal regulatory frameworks correlate with improved compliance rates even in developing economy contexts.

India requires a dedicated, technology-adaptive legal framework explicitly recognizing e-pharmacies and establishing appropriate regulatory standards. The framework should incorporate mandatory registration with the Central Licensing Authority, robust prescription verification through integration with digital health infrastructure, clear resolution of interstate commerce ambiguities, comprehensive healthcare-specific data protection provisions, quality assurance through pharmaceutical serialization and tracking, differentiated approaches for inventory-based and marketplace models with clear liability allocation, guidance regarding prohibited and Over-the-Counter pharmaceutical categories, enhanced consumer protection mechanisms, professional pharmacist oversight requirements, and robust monitoring and enforcement systems with proportionate penalties.

Implementing such a framework requires addressing challenges including stakeholder resistance from traditional pharmacies, technology infrastructure development needs, prescription verification practical limitations, data protection compliance costs, and enforcement capacity constraints. These challenges necessitate phased implementation approaches, capacity building initiatives, collaborative public-private mechanisms, and continued stakeholder engagement.

The imperative for regulatory action is clear. Judicial interventions from multiple High Courts reflect growing recognition that prolonged governmental inaction creates untenable situations compromising both public health protection and legitimate business operations. The Delhi High Court's repeated directives demanding policy formulation underscore judicial concern regarding regulatory abdication of responsibility.

E-pharmacies should neither be banned through excessive precaution stifling beneficial innovation, nor left unregulated through misplaced faith in market self-correction. The appropriate policy response is a balanced, evidence-based regulatory framework enabling the legitimate potential of digital pharmaceutical distribution while rigorously protecting patient safety, pharmaceutical quality, data privacy, and consumer rights. Only through such a comprehensive, dedicated legal framework can India harness the transformative potential of e-pharmacies while fulfilling the state's constitutional obligation to protect public health under Article 47 of the Constitution.

The pharmaceutical sector stands at a critical juncture. Decisive regulatory action establishing clear, comprehensive e-pharmacy governance would provide legal certainty for businesses, ensure patient safety through appropriate oversight, protect sensitive health data through robust privacy provisions, prevent counterfeit pharmaceutical infiltration through quality assurance mechanisms, and ultimately enhance pharmaceutical accessibility for India's vast population. The time for regulatory clarity has arrived; continued delay serves neither public health nor economic development interests.

Suggestions for Future Research

While this research provides comprehensive analysis of e-pharmacy regulatory gaps and proposes a framework for reform, several areas merit further investigation:

1. **Empirical analysis of e-pharmacy safety outcomes:** Comparative studies examining adverse event rates, medication error frequencies, and counterfeit pharmaceutical detection between traditional and e-pharmacy channels would provide evidence regarding actual safety impacts, informing risk-proportionate regulatory approaches.

2. **Economic impact assessment of regulatory alternatives:** Detailed analysis of compliance costs, market access implications, and competitive effects of various regulatory approaches would enable evidence-based policy selection balancing safety with economic efficiency.

3. **Technology evaluation for prescription verification:** Research examining effectiveness, accuracy, and cost-effectiveness of various prescription authentication technologies including AI-based fraud detection, blockchain-based prescription tracking, and biometric verification could guide technology standard development.

4. **Patient outcomes research:** Studies examining medication adherence, health outcomes, and patient satisfaction comparing traditional and e-pharmacy pharmaceutical access would provide patient-centered evidence for policy development.

5. **Comparative regulatory impact analysis:** Longitudinal studies examining regulatory framework impacts in jurisdictions with established e-pharmacy regulations could provide lessons for Indian policy development.

6. **Rural accessibility impact:** Research specifically examining how e-pharmacy availability affects pharmaceutical access in rural and underserved areas would inform policies regarding geographical equity in healthcare access.

These research directions would contribute to an evolving evidence base supporting adaptive, effective e-pharmacy regulation responding to technological advancement and operational experience accumulation.

References

[1] Ministry of Health and Family Welfare, Draft E-Pharmacy Rules (2018), G.S.R. 817(E), available at https://www.pib.gov.in/PressReleasePage.aspx?PRID=2154213.
[2] Regulation of Online Pharmacies in India, SCC TIMES (Nov. 2, 2023), https://www.scconline.com/blog/post/2023/11/02/regulation-of-online-pharmacies-in-india/.
[3] Facilitators, Barriers, and Potential Impacts of Implementation of e-Pharmacy in India and its Potential Impact on Cost, Quality, and Access to Medicines: Scoping Review, PMC (Oct. 8, 2024), https://pmc.ncbi.nlm.nih.gov/articles/PMC11499724/.
[4] Online Pharmacy Industry Seeks Regulatory Clarity, TIMES OF INDIA (Dec. 5, 2019), https://timesofindia.indiatimes.com/business/india-business/online-pharmacy-industry-seeks-regulatory-clarity/articleshow/72391164.cms.
[5] Drugs and Cosmetics Act, No. 23 of 1940, INDIA CODE (1940).
[6] The Rise of E-pharmacy in India: Benefits, Challenges, and the Road Ahead, PMC (Oct. 5, 2022), https://pmc.ncbi.nlm.nih.gov/articles/PMC9804119/.
[7] Drugs and Cosmetics Act § 3, No. 23 of 1940, INDIA CODE (1940).
[8] Drugs and Cosmetics Act § 33, No. 23 of 1940, INDIA CODE (1940).
[9] Drugs and Cosmetics Rules, 1945, Rules 59, 61, 62.
[10] Emerging E-pharmacy Sector in India, INDIAN J. MED. ETHICS 1, 2 (2025), https://ijme.in/wp-content/uploads/2025/05/COMMENTARY-Haripriya-1.pdf.
[11] Pharmacy Act, No. 8 of 1948, INDIA CODE (1948).
[12] Pharmacy Practice Regulations, 2015.
[13] Information Technology Act, No. 21 of 2000, INDIA CODE (2000).
[14] Information Technology Act § 2(1)(w), No. 21 of 2000, INDIA CODE (2000).
[15] Information Technology Act § 79, No. 21 of 2000, INDIA CODE (2000).
[16] Regulation of Digital Healthcare in India: Ethical and Legal Challenges, PMC (Mar. 20, 2023), https://pmc.ncbi.nlm.nih.gov/articles/PMC10048681/.
[17] Ministry of Health and Family Welfare, Draft E-Pharmacy Rules (2018), G.S.R. 817(E), available at https://www.pib.gov.in/PressReleasePage.aspx?PRID=1946709.
[18] Draft Rules for Operation of E-Pharmacies in India, NOVOJURIS (Aug. 21, 2023), https://www.novojuris.com/thought-leadership/draft-rules-for-operation-of-e-pharmacies-in-india.html.
[19] Sale of Addictive Pain Killers/Psychotropic Drugs by Online Pharmacies, PRESS INFO. BUREAU (Aug. 27, 2018), https://www.pib.gov.in/PressReleasePage.aspx?PRID=2154213.
[20] Finalization of Draft Rules on Sale of Drugs by E-Pharmacies, PRESS INFO. BUREAU (Aug. 27, 2018), https://www.pib.gov.in/PressReleasePage.aspx?PRID=1575553.
[21] The Drugs, Medical Devices, and Cosmetics Bill, 2023, SWANITI INITIATIVE (Sept. 12, 2024), https://www.swaniti.com/the-drugs-medical-devices-and-cosmetics-bill-2023/.
[22] Drugs, Medical Devices and Cosmetics Bill, 2023: An Attempt at Comprehensive Reform, MAJMUDAR INDIA (Sept. 6, 2023), https://www.majmudarindia.com/drugs-medical-devices-and-cosmetics-bill-2023-update/.
[23] E-Pharmacies Likely on the Radar of The New Drugs, Medical Devices & Cosmetics Bill 2023, CNBC TV18 (July 23, 2023), https://www.cnbctv18.com/healthcare/india-latest-draft-bill-proposes-strict-curbs-on-online-sale-of-drugs-major-blow-to-e-pharmacies-17309611.htm.
[24] Regulation of E-Pharmacies in India, SPICE ROUTE LEGAL (Oct. 28, 2024), https://spiceroutelegal.com/publications/regulation-of-e-pharmacies-in-india/.
[25] Drugs and Cosmetics Rules, 1945, Rules 59, 61, 62.
[26] Emerging E-pharmacy Sector in India, supra note 10, at 3.
[27] The Rise of E-pharmacy in India, supra note 6, at 5.
[28] Strengthening Pharmaceutical Law and Telepharmacy Regulation in India: A Comprehensive Analysis of Legal Frameworks, Local Administrative Challenges, and Policy Recommendations for Equitable Healthcare Delivery, LEX LOCALIS (Aug. 11, 2025), https://lex-localis.org/index.php/LexLocalis/article/view/801534.

[29] Most E-pharmacies in India Fail to Meet Basic Standards: Study, TIMES OF INDIA (May 2, 2025), https://timesofindia.indiatimes.com/city/hyderabad/most-e-pharmacies-in-india-fail-to-meet-basic-standards-study/articleshow/120574623.cms.
[30] The Regulation of Online Pharmacies (E-Pharmacy), AIDCOC, http://aidcoc.in/pdf/9-E.Pharmacy Regulation Article by Dr.BR Jagashetty.pdf.
[31] Regulation of Digital Healthcare in India, supra note 16.
[32] Information Technology Act, No. 21 of 2000, INDIA CODE (2000).
[33] Draft Rules for Operation of E-Pharmacies in India, supra note 18.
[34] Most E-pharmacies in India Fail to Meet Basic Standards, supra note 29.
[35] The Rise of E-pharmacy in India, supra note 6, at 6.
[36] Regulation of E-Pharmacies in India, supra note 24.
[37] Information Technology Act § 79, No. 21 of 2000, INDIA CODE (2000).
[38] Emerging E-pharmacy Sector in India: Ethical and Regulatory Concerns, INDIAN J. MED. ETHICS (Oct. 9, 2025), https://ijme.in/articles/emerging-e-pharmacy-sector-in-india-ethical-and-regulatory-concerns/.
[39] The Regulation of Online Pharmacies (E-Pharmacy), supra note 30.
[40] Draft E-Pharmacy Rules, supra note 17.
[41] Most E-pharmacies in India Fail to Meet Basic Standards, supra note 29.
[42] Regulation of Online Pharmacies in India, supra note 2.
[43] Tamil Nadu Chemists and Druggists Ass'n v. Union of India, W.P. No. 4111 of 2016 (Mad. H.C. Dec. 2018).
[44] Madras HC Directs Govt to Frame Policy on E-Pharmacies, MEDIANAMA (July 8, 2024), https://www.medianama.com/2024/07/223-madras-hc-directs-centre-policy-e-pharmacies/.
[45] Why Retail Pharmacies Have a Bone to Pick with Their Online Counterparts, YOUR STORY (July 1, 2024), https://yourstory.com/2024/07/explainer-legal-tussles-within-indian-pharma-e-pharmacies.
[46] Dr. Zaheer Ahmed v. Union of India, W.P.(C) 11711/2018 (Del. H.C. Dec. 12, 2018).
[47] Delhi High Court Imposes Ban on Online Sales of Medicines, SS RANA & CO. (Feb. 7, 2024), https://ssrana.in/articles/india-delhi-high-court-imposes-ban-on-online-sales-of-medicines/.
[48] Madras HC Directs Govt to Frame Policy on E-Pharmacies, supra note 44.
[49] Ryan Haight Online Pharmacy Consumer Protection Act of 2008, Pub. L. No. 110-425, 122 Stat. 4820 (2008).
[50] Regulation of Online Pharmacies in India, supra note 2.
[51] General Pharmaceutical Council, Standards for Registered Pharmacies (UK), available at https://www.pharmacyregulation.org/.
[52] Regulation of Online Pharmacies in India, supra note 2.
[53] Most E-pharmacies in India Fail to Meet Basic Standards, supra note 29.
[54] Id.
[55] The Drugs, Medical Devices, and Cosmetics Bill, 2023, supra note 21.
[56] Draft E-Pharmacy Rules, supra note 17.
[57] Strengthening Pharmaceutical Law and Telepharmacy Regulation in India, supra note 28.
[58] Id.
[59] Emerging E-pharmacy Sector in India, supra note 10, at 3.
[60] Digital Personal Data Protection Act, No. 22 of 2023, INDIA CODE (2023).
[61] Draft Rules for Operation of E-Pharmacies in India, supra note 18.
[62] The Rise of E-pharmacy in India, supra note 6, at 6.
[63] Draft E-Pharmacy Rules, supra note 17.
[64] Id.
[65] Most E-pharmacies in India Fail to Meet Basic Standards, supra note 29.
[66] Pharmacy Act, No. 8 of 1948, INDIA CODE (1948); Pharmacy Practice Regulations, 2015.
[67] Strengthening Pharmaceutical Law and Telepharmacy Regulation in India, supra note 28.
[68] Why Retail Pharmacies Have a Bone to Pick with Their Online Counterparts, supra note 45.
[69] The Rise of E-pharmacy in India, supra note 6, at 7.
[70] Regulation of Digital Healthcare in India, supra note 16.
[71] Id.
[72] Strengthening Pharmaceutical Law and Telepharmacy Regulation in India, supra note 28.